Is treatment of insulin resistance beneficial independent of glycemia?
暂无分享,去创建一个
[1] Erik Jørgensen,et al. Low restenosis rate of the NIR coronary stent: results of the Danish multicenter stent study (DANSTENT)--a randomized trial comparing a first-generation stent with a second-generation stent. , 2003, American heart journal.
[2] K. Tanabe,et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. , 2003, American heart journal.
[3] D. Simonson,et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. , 2003, Diabetes care.
[4] J. Shaw,et al. The prevention of type 2 diabetes--lifestyle change or pharmacotherapy? A challenge for the 21st century. , 2003, Diabetes research and clinical practice.
[5] M. Jensen,et al. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. , 2003, Diabetes care.
[6] G. Reaven,et al. Insulin resistance as a predictor of age-related diseases. , 2001, The Journal of clinical endocrinology and metabolism.
[7] S. Aronoff,et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.
[8] T. Shoji,et al. Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Vessel wall properties in type 2 diabetes. , 1999, Diabetes care.
[9] A. Aljada,et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? , 2001, The Journal of clinical endocrinology and metabolism.
[10] W. Koenig,et al. Antidiabetic PPAR&ggr;-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease , 2003 .
[11] A. Aljada,et al. Nuclear Factor-κB Suppressive and Inhibitor-κB Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action?1 , 2001 .
[12] S. Haffner,et al. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.
[13] W. März,et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. , 2003, Diabetes care.
[14] M. Hanefeld,et al. Rosiglitazone Improves Postprandial Glycemia and Markers of Endothelial Function in Patients with Type 2 Diabetes , 2002 .
[15] A. Aljada,et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. , 2001, The Journal of clinical endocrinology and metabolism.
[16] F. Logerfo,et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. , 2003, Metabolism: clinical and experimental.
[17] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[18] L. Fink,et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. , 1998, Journal of diabetes and its complications.
[19] Aldons J. Lusis,et al. Atherosclerosis : Vascular biology , 2000 .
[20] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[21] W. Koenig,et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[22] H. Lebovitz,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .
[23] H. Koshiyama,et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.
[24] J. Brunzell,et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. , 2002, The American journal of cardiology.
[25] S. O’Rahilly,et al. The perils of portliness: causes and consequences of visceral adiposity. , 2000, Diabetes.
[26] K. Nakao,et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.
[27] C. Tack,et al. Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects , 1998, Diabetes Care.
[28] J. Cohn. Vascular wall function as a risk marker for cardiovascular disease. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[29] B. Howard,et al. Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.
[30] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[31] V. Fonseca,et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. , 1998, The Journal of clinical endocrinology and metabolism.
[32] Ralph B D'Agostino,et al. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. , 2002, Diabetes care.
[33] S. Anderson,et al. Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose Intolerance: An Integrated Index of Vascular Function? , 2002, Circulation.
[34] S. Tanaka,et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.
[35] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[36] Fernando Costa,et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph , 2003, Circulation.
[37] S. Haffner,et al. Predicting future cardiovascular disease: do we need the oral glucose tolerance test? , 2002, Diabetes care.
[38] E. Ferrannini,et al. Troglitazone Reduces LDL Oxidation and Lowers Plasma E-selectin Concentration in NIDDM Patients , 1998, Diabetes.
[39] J. Toole,et al. Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.